Unlocking the future of drug discovery and development
The world of biopharmaceutical research is constantly evolving, and the key to creating innovative, effective treatments including novel gene therapies lies in identifying and leveraging clinically actionable genes. This focus gives biopharma companies a unique edge, allowing them to develop treatments that can truly make a difference. With breakthroughs in genomics and the incredible database offered by Kyvor Genomics, we're on the brink of a transformation in drug discovery like never before.
The biopharma challenge: Expensive and time-consuming R&D
Despite technological advancements, biopharma research still faces significant hurdles. Traditional drug R&D is costly and time-consuming, plagued by high failure rates and long development timelines.
Elevate healthcare with patient-centered research
Kyvor Genomics utilizes advanced Next-Generation Sequencing (NGS) technology to provide biopharma companies with comprehensive genomic data analyzing 20,000+ genes, including 2,500 cancer-related genes and 50 million RNA reads. This detailed profiling includes Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI) assessments and homologous recombination deficiency (HRD) wherever applicable, delivering clinically actionable insights and variance of unknown significance (VUS) that accelerate drug discovery.
Providing DNA data from 40,000+ patients can significantly enhance drug discovery for biopharma companies by identifying new clinically actionable genomes and biomarkers. This extensive dataset allows researchers to uncover a broad spectrum of genetic mutations and variations associated with cancer and other diseases, identifying novel drug targets crucial for many diseases.
Analyzing this large cohort helps discover unique and common disease-driving mutations, revealing key molecular pathways and mechanisms. This facilitates the discovery of targets for new drugs. Additionally, the dataset enables the identification of predictive and prognostic biomarkers, guiding the selection of effective drug targets for specific patient populations.
Why choose us?
